Genfit

Genfit moves to jump-start enrollment in slow-going phase 2 liver failure trial
Fierce Biotech
Fri, 09/20/24 - 11:10 am
Genfit
liver failure
clinical trials
VS-01
FDA grants accelerated approval to Genfit and Ipsen's liver disease drug
Reuters
Mon, 06/10/24 - 06:02 pm
Genfit
Ipsen
FDA
Ocaliva
primary biliary cholangitis. liver disease
Ipsen/Genfit eye June FDA verdict for liver drug elafibranor
Pharmaphorum
Thu, 12/7/23 - 11:01 am
Genfit
Ipsen
elafibranor
primary biliary cholangitis
FDA
priority review
Ipsen, eyeing approval, reveals mixed liver disease data on challenger to Intercept and CymaBay
Fierce Biotech
Tue, 11/14/23 - 09:20 am
Ipsen
Genfit
elafibranor
liver disease
Intercept Pharma
CymaBay Therapeutics
Ipsen and Genfit to file for EMA and FDA approval for elafibranor
Clinical Trials Arena
Fri, 06/30/23 - 10:12 am
Ipsen
Genfit
EMA
FDA
elafibranor
liver disease
primary biliary cholangitis
Genfit Restructuring Cuts Staff by 40%, Creates Two New Subsidiaries
Xconomy
Wed, 09/30/20 - 10:58 pm
Genfit
NASH
restructuring
layoffs
Genfit abandons late-stage trial of NASH drug elafibranor
Pharmaforum
Thu, 07/23/20 - 10:39 am
Genfit
elafibranor
NASH
clinical trials
Biotech Genfit warns costs of failed NASH trial will drag deep into 2020
Fierce Biotech
Tue, 05/19/20 - 10:29 am
Genfit
NASH
clinical trials
elafibranor
Genfit Contender in Heated NASH Drug Race Fails in Phase 3 Study
Xconomy
Mon, 05/11/20 - 11:50 pm
Genfit
clinical trials
NASH
elafibranor
The crucial data readouts coming soon for small biotechs
EP Vantage
Thu, 04/23/20 - 12:37 pm
clinical trials
Akebia
Blueprint Medicines
Genfit
TG Therapeutics
vadadustat
Ayvakit
elafibranor
Akero Heads to Top of Class in NASH; Genfit Says Pandemic Won’t Delay Data
Xconomy
Mon, 04/13/20 - 11:04 am
Akero
Genfit
NASH
COVID-19 not expected to 'significantly delay' Genfit's phase 3 NASH readout
Fierce Biotech
Tue, 03/31/20 - 11:04 am
Genfit
NASH
clinical trials
COVID-19
elafibranor
Genfit's NASH key phase 3 data delayed
Fierce Biotech
Fri, 02/21/20 - 10:32 am
Genfit
NASH
clinical trials
elafibranor
#JPM20: After Year of NASH collapses, all eyes on two biotechs
Endpoints
Thu, 01/16/20 - 10:14 am
NASH
JPMHC 20
Genfit
Gilead Sciences
Will we see the world's first approved NASH drug in 2020?
Fierce Biotech
Fri, 12/20/19 - 10:20 am
NASH
Intercept Pharma
Genfit
As NASH shifts again, the focus remains on Genfit’s big readout
EP Vantage
Wed, 12/18/19 - 10:53 am
NASH
Genfit
elafibranor
Pfizer
Boehringer Ingelheim
Gilead Sciences
Poxel
Takeda
Intercept Pharma
Genfit trumpets new NASH blood biopsy data
Pharmaforum
Tue, 11/12/19 - 08:01 pm
Genfit
NASH
diagnostics
liquid biopsy
Genfit’s liver disease Hail Mary approaches
EP Vantage
Thu, 09/19/19 - 08:10 pm
Genfit
NASH
elafibranor
As Genfit hopes to get its liver drug on the market, founding CEO makes way for new blood
Fierce Biotech
Tue, 09/3/19 - 11:04 am
Genfit
Pharma CEOs
François Mouney
Pascal Prigent
NASH drugmaker stocks rebound after dip on FDA guidance
Biopharma Dive
Mon, 06/10/19 - 06:08 pm
NASH
FDA
Madrigal Pharmaceuticals
Viking Therapeutics
Intercept Pharma
Genfit

Pages